{
    "clinical_study": {
        "@rank": "107792", 
        "acronym": "RESPONSE", 
        "arm_group": [
            {
                "arm_group_label": "NT100", 
                "arm_group_type": "Experimental", 
                "description": "NT100 Dose 1"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous\n      NT100 in pregnant women with a history of unexplained recurrent pregnancy loss.\n      Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo."
        }, 
        "brief_title": "A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Pregnancy Loss", 
            "Recurrent Miscarriage"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Abortion, Spontaneous", 
                "Abortion, Habitual"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous\n      NT100 in pregnant women with a history of unexplained recurrent pregnancy loss.\n      Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo.\n      Participants will be screened for eligibility, and will begin attempts at spontaneous\n      conception. Following randomization and initiation of study drug treatment, participants\n      will visit the study site at specified intervals throughout the study for assessments and\n      blood work.\n\n      All participants will be monitored for adverse events. All participants who have received at\n      least one dose of study drug will be followed for safety for a minimum of 4 weeks following\n      the last dose of study drug. After delivery, pregnancy outcome information will be obtained."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pre-menopausal female 18-37 years of age at consent, trying to conceive\n\n          2. Documented history of unexplained recurrent pregnancy loss\n\n          3. Spontaneous conception, as confirmed by urine pregnancy test performed at the\n             investigative site\n\n          4. Body mass index (BMI) of 19-35 kg/m2 at consent\n\n        Exclusion Criteria:\n\n          1. Greater than 5 weeks of gestation when presenting for randomisation.\n\n          2. Known karyotype abnormalities in either the participant or her current male partner\n\n          3. Uncorrected clinically significant intrauterine abnormalities\n\n          4. Abnormal vaginal bleeding of unknown cause\n\n          5. Current diagnosis of infertility in either the participant or her current male\n             partner\n\n          6. Current or past diagnosis of systemic autoimmune disease, coagulopathy,\n             hyperprolactinemia, cervical incompetence, or high-grade cervical dysplasia with\n             conization/surgery.\n\n          7. Any uncontrolled clinically significant medical condition"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "37 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156063", 
            "org_study_id": "NT-05"
        }, 
        "intervention": [
            {
                "arm_group_label": "NT100", 
                "intervention_name": "NT100", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Recurrent Pregnancy Loss", 
            "Recurrent Miscarriage", 
            "Miscarriage", 
            "Pregnancy Loss", 
            "Repeated Pregnancy Loss"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "Response Study website", 
            "url": "http://www.responseresearchstudy.co.uk"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Ashington", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Coventry", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Frimley, Surrey", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Middlesbrough", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Newcastle upon Tyne", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "South Shields", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Southamptom", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "responseresearchstudy.co.uk"
                }, 
                "facility": {
                    "address": {
                        "city": "Sunderland", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)", 
        "overall_contact": {
            "email": "response@noratherapeutics.com", 
            "last_name": "Mark Joing", 
            "phone": "+1-650-353-5520"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is clinical pregnancy at Week 20 of gestation", 
            "measure": "Clinical Pregnancy", 
            "safety_issue": "No", 
            "time_frame": "at Week 20 of gestation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Live birth", 
                "safety_issue": "No", 
                "time_frame": "at any time during pregnancy"
            }, 
            {
                "measure": "Clinical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 6, 8 and 12 of gestation"
            }, 
            {
                "measure": "Spontaneous pregnancy loss", 
                "safety_issue": "No", 
                "time_frame": "within 24 weeks of gestation"
            }, 
            {
                "measure": "Stillbirth", 
                "safety_issue": "No", 
                "time_frame": "after 24 weeks of gestation"
            }, 
            {
                "measure": "Subjects with adverse events and serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "during treatment and within 4 weeks after treatment"
            }, 
            {
                "measure": "Changes in clinical laboratory parameters following study drug exposure", 
                "safety_issue": "No", 
                "time_frame": "during treatment and within 4 weeks after treatment"
            }
        ], 
        "source": "Nora Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nora Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}